PMBCL
Haematology · 2018–2020
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pembrolizumab Relapsed or refractory primary mediastinal B-cell lymphoma (R/R PMBCL) in adult and paediatric patients. | Mar 2020 | Recommended with restriction | 1 individuals Lymphoma Australia · Leukaemia Foundation |
| pembrolizumab Treatment of relapsed or refractory primary mediastinal large B-cell lymphoma (R/R PMBCL). | Nov 2018 | Not recommended | 3 individuals Lymphoma Australia |
Who spoke
Lymphoma Australia · Leukaemia Foundation
What the PBS pays
$740M in government benefit over 2024–25, across 87,155 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| pembrolizumab | $739.6M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.